Evidence map›Paper›PMID 41215786›Full record

ArticleClinical kidney journal2025

Novel biomarkers of crescentic glomerulonephritis identified by urinary proteomics.

Shuo Zhang, Xin Chen, Jiatong Xu, Yuting Hu, Yin Wang, Peng Xia, Bintao Qiu, Limeng Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuo ZhangDepartment of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0001-8171-2779
Xin ChenDepartment of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Jiatong XuDepartment of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yuting HuDepartment of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yin WangDepartment of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Peng XiaDepartment of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Bintao QiuState Key Laboratory of Complex Severe and Rare Diseases, Medical Research Center, PUMCH, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Limeng ChenDepartment of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, PUMCH, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0002-8425-5742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Crescentic glomerulonephritis (CrGN) with rapidly progressive renal function loss necessitates prompt pathology diagnosis and treatment. Non-invasive biomarkers are crucial in cases where renal biopsy is unavailable or unsuitable. Urinary proteomics, particularly data-independent acquisition (DIA) proteomics, might provide potential indicators. Methods: We recruited crescentic nephritis proved by renal biopsy at Peking Union Medical College Hospital (PUMCH) from May 2022 to April 2023 and age-matched nephritis, acute kidney injury (AKI), and health controls. The CrGN group is the patients with extensive glomerular crescents over 50%. We performed liquid chromatography with tandem mass spectrometry analysis to identify differentially expressed proteins (DEPs), ingenuity pathway analysis (IPA), and the proteome map for significant pathways and crucial proteins among patients and controls, then validated using enzyme-linked immunosorbent assay analysis. Results: We enrolled a total of 137 participants, 55 in the proteomics cohort [15 CrGN (Type I: Conclusion: By non-invasive urine proteomics, the new biomarkers F5/UCr and PLTP/UCr hold promise in identifying the CrGN patient.

Indexed as

crescentic nephritisdata-independent acquisition proteomics (DIA)urine biomarkers

Identifiers

PMID41215786
PMCPMC12596191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.